סאקסנדה^® - יחד מטפלים בהשמנה

Therapeutic indications Adults Saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of

• ≥ 30 kg/m² (obesity), or
• ≥ 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related

comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, or dyslipidaemia and who have failed a previous weight management intervention. Treatment with Saxenda should be discontinued after 12 weeks on the 3.0 mg/day dose if patients have not lost at least 5% of their initial body weight. Adolescents (≥12 years) Saxenda can be used as an adjunct to a healthy nutrition and increased physical activity for weight management in adolescent patients from the age of 12 years and above with:

• obesity (BMI corresponding to ≥30 kg/m2 for adults by international cut-off points) and
• body weight above 60 kg.

Treatment with Saxenda should be discontinued and re-evaluated if patients have not lost at least 4% of their BMI or BMI z score after 12 weeks on the 3.0 mg/day or maximum tolerated dose. Reevaluation should be performed periodically. should be performed periodically.

1.Physician Leaflet approved by MOH Saxenda Jan 2022.